(Q33928608)

30 July 2017

1 reference

title

Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents (English)

1 reference

30 July 2017

Burt T

1

1 reference

PubMed ID

11122998

30 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Current Psychiatry Reports

30 July 2017

1 reference

30 July 2017

2

1 reference

30 July 2017

6

1 reference

30 July 2017

473-478

1 reference

https://scigraph.springernature.com/pub.10.1007/s11920-000-0005-7

30 July 2017

0 references

cites work

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Donepezil improves symptoms of delirium in dementia: implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Orbital and Dorsolateral Frontal Perfusion Defect Associated With Behavioral Response to Cholinesterase Inhibitor Therapy in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11920-000-0005-7

Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

21 January 2018

1 reference

12 December 2020

Cholinergic therapy for Down's syndrome

1 reference

12 December 2020

Donepezil in treatment-resistant bipolar disorder.

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis

1 reference

12 December 2020

Acetylcholine and affective disorder

1 reference

12 December 2020

Depressive response to physostigmine challenge in borderline personality disorder patients

1 reference

12 December 2020

Cholinergic reversal of manic symptoms

1 reference

12 December 2020

Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects

1 reference

12 December 2020

The administration of di-isopropyl fluorophosphate (DFP) to man; effect on the central nervous system with special reference to the electrical activity of the brain.

1 reference

12 December 2020

Donepezil for Tourette's disorder and ADHD

1 reference

12 December 2020

Specificity of the Pyridostigmine/Growth Hormone Challenge in the Diagnosis of Depression

1 reference

12 December 2020

SOME BEHAVIORAL CHANGES IN MAN FOLLOWING ANTICHOLINESTERASE ADMINISTRATION

1 reference

12 December 2020

Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis

1 reference

12 December 2020

A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments

1 reference

12 December 2020

Treating visual hallucinations with donepezil

1 reference

12 December 2020

Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.

1 reference

12 December 2020

Is cholinergic sensitivity a genetic marker for the affective disorders?

1 reference

12 December 2020

Cholinergic reversal of manic symptoms

1 reference

12 December 2020

The central effects of scopolamine in man.

1 reference

12 December 2020

The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.

1 reference

12 December 2020

Enhanced growth hormone responses to pyridostigmine challenge in patients with panic disorder.

1 reference

12 December 2020

Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release.

1 reference

12 December 2020

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease

1 reference

12 December 2020

Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change

1 reference

12 December 2020

Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

1 reference

12 December 2020

Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.

1 reference

12 December 2020

Donepezil (Aricept) therapy for Alzheimer's disease.

1 reference

12 December 2020

Donepezil for behavioural disorders associated with Lewy bodies: a case series

1 reference

12 December 2020

Learning and memory in bipolar and unipolar major depression: effects of aging.

1 reference

12 December 2020

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

12 December 2020

A cholinergic-adrenergic hypothesis of mania and depression

1 reference

12 December 2020

Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.

1 reference

12 December 2020

10.1007/S11920-000-0005-7

Identifiers

DOI

1 reference

PubMed ID

11122998

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

11122998